ImmPACT Bio is dedicated to the discovery of transformative CAR-T cell therapies for cancer patients who have exhausted their treatment options. Our technology is designed to precisely distinguish cancerous cells from normal cells; thereby eliminating tumors without damaging normal tissues. Our goal is to eradicate tumors without generating the severe side effects that are difficult, sometimes impossible, for cancer patients to endure. The company was founded in 2017 in the FuturRx incubator (Israel). In 2019, ImmPACT Bio was incorporated in the US and R&D operations were established in Camarillo, CA. In 2021 ImmPACT Bio merged with Kalthera.
